First COPD Nebulized Triple Therapy Showcased by Glenmark

Glenmark Pharmaceuticals has introduced the world’s first nebulized triple therapy for COPD, strengthening its position as a leader in advanced drug manufacturing.

The two new products — Nebzmart GFB Smartules and Glenmark Airz FB Smartules — combine Glycopyrronium, Formoterol, and Budesonide in a fixed-dose nebulized format designed to simplify treatment for patients who face challenges with MDIs and DPIs.

Behind this milestone is Glenmark’s long-term focus on precision manufacturing and large-scale production of complex respiratory treatments. The development of this nebulized triple therapy reflects the company’s ability to bring innovative combinations into stable, easy-to-administer formats.

Also Read: How Integrated Logistics Hubs Are Reshaping Regional Trade

"At Glenmark, innovation is about reimagining and redefining how therapies reach patients. With Nebzmart GFB Smartules and Glenmark Airz FB Smartules, the world’s first nebulized triple therapy for COPD, we are transforming respiratory care,” said Alok Malik, President & Business Head, India Formulations, Glenmark Pharmaceuticals.

Clinical studies conducted in India reported rapid lung function gains and improved control of dyspnea, with the therapy showing strong tolerability. This gives patients a single-format solution that reduces the handling steps linked to multiple inhaler types. “This launch represents a significant advancement in the management of COPD and demonstrates our focus in strengthening global respiratory leadership,” said Dr Monika Tandon, Global Head of Clinical Development, Glenmark Pharmaceuticals.

Glenmark’s global network of 11 manufacturing facilities across four continents enables consistent production and supply of high-quality medicines. With operations in over 80 countries, the company continues to scale its capabilities in key areas such as respiratory, dermatology, and oncology.